<DOC>
	<DOCNO>NCT00722774</DOCNO>
	<brief_summary>In 20th century , influenza pandemic occur 1918 , 1957 , 1968 , associate significant morbidity mortality . It estimate , United States alone , next influenza pandemic could cause approximately 200,000 death 750,000 hospitalization . Thus , development vaccine potential influenza strain become priority . The purpose study determine safety immune response H2N2 influenza vaccine candidate .</brief_summary>
	<brief_title>Safety Immune Response Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine</brief_title>
	<detailed_description>H2N2 influenza virus emerge 1950s replace circulate H1N1 human influenza virus . The first case occur China 1956 , disease become widespread 1956-1957 , result `` Asian Influenza '' pandemic responsible 1 4 million death worldwide . H2N2 viruses circulate since 1968 , replace H3N2 influenza virus resurgence H1N1 virus . For reason , large proportion population susceptible infection H2N2 influenza . If subtype re-emerges , could potentially cause next pandemic . This vaccine , therefore , important priority development vaccine potential pandemic influenza strain . This vaccine trial conduct Center Immunization Research isolation unit Mason F. Lord Building Johns Hopkins Bayview Medical Center ( Baltimore , MD ) . The study initiate April 1st December 20th , 2008 , wild-type influenza unlikely circulate Baltimore area . An individual 's participation study last approximately 90 day . All participant receive two vaccination approximately 4 - 8 week apart . After vaccination , participant remain isolation study site least nine day rRT-PCR assay influenza negative 2 consecutive day . A physical examination nasal wash occur day isolation period . Blood collection occur isolation begin Day 7 release . Follow-up outpatient visit schedule Days 28 56 first vaccination Day 28 second vaccination . Follow-up visit include serum collection , nasal wash , interim medical history .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>General good health Available duration trial If female , agree use effective birth control method duration study . More information criterion find protocol . Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease . More information criterion find protocol . Behavioral cognitive impairment psychiatric disease , opinion investigator , intereferes study Previous receipt FluMist intranasal live attenuate influenza vaccine Previous enrollment H2N2 influenza vaccine trial study avian influenza vaccine Seropositive H2N2 influenza A virus ( serum HAI titer &gt; 1:8 ) Positive urine drug toxicology test indicate narcotic use and/or dependency define Drug Enforcement Agency Medical , occupational , family problem result alcohol illicit drug use within 12 month prior study entry Any condition , opinion investigator , would interfere study History anaphylaxis Allergy oseltamivir determine subject report Current diagnosis asthma reactive airway disease within 2 year prior study entry History GuillainBarre Syndrome HIV1infected Hepatitis Cinfected Positive hepatitis B virus surface antigen Known immunodeficiency syndrome Use corticosteroid ( exclude topical preparation ) immunosuppressive drug within 30 day prior study entry Receipt live vaccine within 4 week kill vaccine within 2 week prior study entry History surgical splenectomy Receipt blood bloodderived product ( include immunoglobulin ) within 6 month prior study entry Current smoker unwilling stop smoking duration study . More information criterion find protocol . Travel Southern Hemisphere within 14 day prior study entry Travel cruise ship within 14 day prior study entry Direct contact live poultry within 14 day prior study study completion . Receipt another investigational vaccine drug within 30 day prior study entry Allergy egg egg product Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Influenza</keyword>
</DOC>